Maayke Hunfeld

67 Review neuromonitoring Outcome score Follow up interval Results Morta- lity (%) Limitations Grade Primary: PCPC (change <2 = good outcome) Hospital discharge Secondary: survival Primary: -NSE higher in pts with poor outcome at 48 hrs, 72 hrs and 96 hrs, all P<0.001) -S100b no sign difference with poor outcome. -Total and active PAI-1 no sign difference Secondary: -Correlation between higher NSE and death at 24 hrs (P=0.004), 48 hrs (P<0.001), 72 hrs (P<0.001) and 96 hrs (P<0.001) -S100b sign associated with death at 48 hrs (p=0.002), 72 hrs (P=0.001) and 96 hrs (p=0.007) in children ≥ 2 yrs -Total and active PAI-1 no sign difference 43% -Samples are missing (died, early discharge, initially other hospital) - No accepted individual cut offs -Heterogeneous pts which may alter baseline levels of biomarkers -Biomarker sampling from peripheral access -Short and crude outcome scale 2B/C Primary: accuracy biomarker concentration to predict PCPC score (1-2-3 = good outcome) Hospital discharge and at 6 months Secondary: Mortality Hospital discharge and 6 months post-CA Additional: -Clinical variables for prediction Primary: -NSE and S100B concentrations increased in the poor vs. good outcome group at 48 and 72 hrs post-ROSC (All P<0.05) -MBP predicted good vs poor outcome at 72 hours (P0.08) Secondary: -All 3 biomarkers predicted mortality at 24 hrs (p < 0.05) -NSE and S-100B increased in subjects who died at all time points ( p < 0.05) Additional: -S100B and NSE superior in predicting poor vs good outcome at 6 mo compared to clinical predictors (CPR-ROSC time, first lactate, blood pH) -MBP positive correlation with subject temperature -Initial NSE and s-100B inversely correlated with age 40% -Small sample size -No cut off values are available -PI was part of medical team -Not all subjects survived to day 7 -Crude outcome scale 2B 2